Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Zonisamide in refractory canine epilepsy
Epilepsy in dogs and men can be very frustrating to control. Which choices are the best if the `normal` drugs like phenobarbital are not effective? Zonisamide, a sulfonamide-derivate, is an antiepileptic for focal and generalized epilepsy in men. It has also some positive effects in dogs.

12 dogs with poorly controlled primary epilepsy were included in this prospective non-comparative study. Oral zonisamide dose was adapted to the desired effective blood levels (10 to 40 ug/dl). The mean dose required was 8,9 mg/kg every 12 hours.

Seven dogs showed a favourable response with a mean reduction of the seizures of 81,3%. Five dogs unfortunately even showed an increased seizure frequency.

Mild side effects like transient sedation, vomiting and diarrhea were seen in 6 (50%) of the treated animals.

Source: Dewey CW, et al (2004): Zonisamide Therapy for Refractory Idiopathic Eiplepsy in Dogs. In: JAAHA 40:§, pp 270-284


Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Variability of SDMA in apparently healthy dogsmembers
Symmetric dimethylarginine (SDMA) is a screening tool for early kidney dysfunction and monitoring treatment in cases of chronic kidney disease (CKD). There are no current studies describing the suitability of this test for use with published population‐based reference intervals. The objectives of this study were to determine the components of biological variability, the index of individuality (IOI), the critical difference between sequential measurements (CD) and the number of measurements required to assess the homeostatic set point (HSP), for both SDMA and serum creatinine (sCr), in apparently healthy dogs.

  • Bioavailability of suppository acetaminophen in dogsmembers
  • Computed tomographic lymphography for lymph node staging in dogs with malignant tumors members
  • Characterization of ocular melanosis-affected canine melanocytesmembers
  • Nasopharyngeal sialoceles in brachycephalic dogsmembers
  • Enterococcus faecium SF68 on serum cobalamin and folate concentrationsmembers
  • Gastrointestinal eosinophilic sclerosing fibroplasia limited to the mesentery in a catmembers
  • Ion acid-base disturbances and associated mortality in dogsmembers
  • First description of ultrasonic bone curette in canine otic surgerymembers
  • Staining hair samples with a modified Wright-Giemsa stain to diagnose feline dermatophytosismembers
  • Oral extended release hydrocodone as analgesia after TPLOmembers
  • 25OH vitamin D3 serum concentration in dogs with acute polyradiculoneuritismembers
  • Type 1 immune mediated polyarthritis in dogs and temporal relationship to vaccination members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved